Browse the evidence

People with physical disabilities (PWD) report more sedentary time compared to people without disabilities (PWoD) (β = 0.34; 95 % CI = 0.16-0.52, p < 0.001).

Practitioners should be aware that PWD may require tailored interventions to reduce sedentary behavior.

PWD have greater odds of reporting zero total physical activity compared to PWoD (OR = 5.18, 95 % CI = 2.19-12.24, p < 0.001).

Interventions for PWD should focus on increasing overall physical activity levels.

The effects of resistance training at longer muscle lengths show an increasing trend from proximal to distal sites.

Practitioners may consider the trend when designing resistance training programs, but should note the trivial nature of the differences.

There was stronger support for general inter-individual response variation (GEN) compared to condition-specific response variation (CON).

Understanding general response variation can help tailor training programs more effectively.

Gross variability in resistance training outcomes often reflects confounding sources of within-participant variation rather than true inter-individual differences.

Practitioners should be cautious in interpreting variability in training outcomes.

GLP-1 receptor agonists have shown promising results in reducing liver enzymes and improving MASLD.

Practitioners may consider GLP-1 RAs as a therapeutic option for MASLD.

The long-acting GIPR agonist LY3537021 induced a mean body weight loss of 3.14 kg in participants with T2D compared to 0.36 kg in the placebo group at day 57 (p < 0.05).

LY3537021 may be an effective treatment option for weight loss in patients with T2D.

LY3537021 was well tolerated with infrequent gastrointestinal adverse events.

LY3537021 may be a safe option for patients with T2D.

GLP-1 receptor agonists (GLP-1RAs) may help manage psoriasis (PsO) and psoriatic arthritis (PsA) in patients with obesity.

Clinicians may consider GLP-1RAs as a treatment option for obese patients with PsO and PsA.

Retatrutide (LY3437943) is a novel triple agonist that targets GLP-1, GIP, and glucagon receptors, representing a transformative advance in obesity pharmacotherapy.

Retatrutide may be considered as a new treatment option for obesity.

Retatrutide shows additional benefits for metabolic comorbidities such as NASH and cardiovascular disease.

Retatrutide may help manage obesity-related metabolic conditions.

Adipocyte browning enhances energy expenditure, improves insulin sensitivity, and mitigates lipid accumulation.

Adipocyte browning could be targeted in therapies for obesity and metabolic diseases.

The degree of muscle-based losses varied widely among the incretin groups.

Individual responses to incretin therapies can vary, necessitating personalized treatment approaches.

Glucagon-like peptide-1 receptor agonists may encourage a more holistic approach to treatment of CKM syndrome.

Clinicians should consider using GLP-1 receptor agonists for integrated treatment strategies.

Higher percentage body fat (PBF) is associated with successful weight reduction in both male (OR = 3.990) and female (OR = 2.266) patients.

Monitoring body fat percentage may help predict weight loss success in patients undergoing GLP-1RA treatment.

Bariatric surgery is associated with a 42.4% reduction in fat mass (FM) at 6 months, 49.7% at 12 months, and 49.7% at 24 months.

Bariatric surgery significantly reduces fat mass in patients over a 24-month period.

Both bariatric surgery and GLP-1RA treatment improve the fat-free mass (FFM) to fat mass (FM) ratio.

Both interventions are effective in improving body composition ratios.

The efficacy of GLP-1 receptor agonists was consistent across other important subpopulations.

GLP-1 receptor agonists can be considered effective for weight loss across diverse patient groups.

Patients show a strong commitment to obtaining and maintaining weight-loss medication despite disruptions to their daily lives.

Health care providers should recognize the dedication of patients in managing their weight-loss treatment.

Health care professionals align patients' expectations for immediate weight loss while navigating moral reasoning about weight loss methods.

Practitioners should be aware of the expectations patients have and the ethical considerations in weight-loss discussions.

Insulin therapy often leads to fat mass accumulation and increases the risk of sarcopenic obesity.

Practitioners should be cautious of insulin therapy's potential to increase fat mass and risk of sarcopenic obesity.

The FDA has conditionally approved Resmetirom as the first pharmacological treatment for MASH.

Clinicians should consider Resmetirom as a treatment option for MASH.

Glucagon-like peptide-1 (GLP-1) receptor agonists are widely prescribed for the treatment of type 2 diabetes and obesity.

Practitioners should consider GLP-1 receptor agonists for managing type 2 diabetes and obesity.

GLP-1 agonists can modulate appetite through effects on the hypothalamus, making them promising for obesity treatment.

GLP-1 agonists may be effective options for patients looking to manage obesity through appetite control.